Trevi Therapeutics, Inc.

NasdaqGM:TRVI Stock Report

Market Cap: US$352.8m

Trevi Therapeutics Management

Management criteria checks 3/4

Trevi Therapeutics' CEO is Jennifer Good, appointed in Mar 2011, has a tenure of 13.83 years. total yearly compensation is $1.69M, comprised of 35.4% salary and 64.6% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth $979.09K. The average tenure of the management team and the board of directors is 3.8 years and 7.7 years respectively.

Key information

Jennifer Good

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage35.4%
CEO tenure13.8yrs
CEO ownership0.3%
Management average tenure3.8yrs
Board average tenure7.7yrs

Recent management updates

Recent updates

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Sep 27
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

May 24
We Think Trevi Therapeutics (NASDAQ:TRVI) Can Afford To Drive Business Growth

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Jan 27
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

Trevi adds 19% on full data set from mid-stage cough study

Sep 19

Trevi Therapeutics: Moving Forward

Sep 11

Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Mar 23
Is Trevi Therapeutics (NASDAQ:TRVI) Using Too Much Debt?

Trevi has a new development chief

Feb 01

CEO Compensation Analysis

How has Jennifer Good's remuneration changed compared to Trevi Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$44m

Jun 30 2024n/an/a

-US$39m

Mar 31 2024n/an/a

-US$34m

Dec 31 2023US$2mUS$597k

-US$29m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$898kUS$523k

-US$29m

Sep 30 2022n/an/a

-US$32m

Jun 30 2022n/an/a

-US$31m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$2mUS$506k

-US$34m

Sep 30 2021n/an/a

-US$35m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$33m

Dec 31 2020US$1mUS$478k

-US$33m

Sep 30 2020n/an/a

-US$30m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$29m

Dec 31 2019US$3mUS$435k

-US$27m

Sep 30 2019n/an/a

-US$28m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$27m

Dec 31 2018US$528kUS$400k

-US$26m

Compensation vs Market: Jennifer's total compensation ($USD1.69M) is about average for companies of similar size in the US market ($USD2.23M).

Compensation vs Earnings: Jennifer's compensation has increased whilst the company is unprofitable.

CEO

Jennifer Good (59 yo)

13.8yrs

Tenure

US$1,687,298

Compensation

Ms. Jennifer L. Good co-founded Trevi Therapeutics, Inc., in March 2011 and has been its Chief Executive Officer and President since March 2011. Ms. Good served as Principal Financial Officer at Trevi Ther...

Leadership Team

NamePositionTenureCompensationOwnership
Jennifer Good
Co-Founder13.8yrsUS$1.69m0.28%
$ 979.1k
Thomas Sciascia
Co-Founder & Chief Scientific Officer13.8yrsUS$977.13k0.29%
$ 1.0m
James Cassella
Chief Development Officerless than a yearUS$112.95k0%
$ 0
Lisa Delfini
Chief Financial Officer3.4yrsno data0.069%
$ 244.5k
Christopher Galletta
Controller & Chief Accounting Officer3.8yrsno data0.026%
$ 91.5k
Katie McManus
Communications Managerno datano datano data
Farrell Simon
Chief Commercial Officerno datano data0.059%
$ 209.5k
Danine Summers
Vice President of Medical Affairsno datano datano data

3.8yrs

Average Tenure

62.5yo

Average Age

Experienced Management: TRVI's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jennifer Good
Co-Founder13.8yrsUS$1.69m0.28%
$ 979.1k
Anne VanLent
Independent Director6.3yrsUS$127.95k0.034%
$ 119.3k
Dominick Colangelo
Independent Director4.6yrsUS$120.45k0%
$ 0
Edward Mathers
Independent Director7.5yrsUS$110.45k0%
$ 0
David Meeker
Independent Chairman of the Board7.5yrsUS$135.45k0.46%
$ 1.6m
Michael Heffernan
Independent Director7.9yrsUS$127.95k0.0083%
$ 29.1k
Jeffrey Bernhard
Member of Clinical Advisory Board11.8yrsno datano data
Dawn McGuire
Member of Clinical Advisory Board11.8yrsno datano data

7.7yrs

Average Tenure

62yo

Average Age

Experienced Board: TRVI's board of directors are considered experienced (7.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 23:21
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Trevi Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.